|
Source
|
Web search |
|
Organization
|
Adagio |
|
Market status
|
Under Development |
|
Industry
|
Medical |
|
Value chain stage
|
Input |
|
Business models
|
B2C |
|
Product categories
|
Medicine |
|
Biotech components
|
Virus |
|
Organization type(s)
|
Private Company |
|
Funding types
|
Private Funding |
|
Known funding amount
|
$50,000,000 USD |
|
Notes
|
“Adagio is working on antibodies that work by binding to a piece of the spike protein that is found on multiple coronaviruses...Adagio is instead using the well-known safety profile of antibodies, which can be administered twice a year and could provide greater than 90% protection against SARS-CoV-2, the company believes...The answer, Gerngross says, is antibodies. Isolating potent antibodies from B cells, a process developed within the past decade, creates the only real “credible solution.” It’s why he chose this approach, also favored by Vir, Eli Lilly, Regeneron and AstraZeneca, but with “a very different angle.” |
Added 4 years ago
Last modified 4 years ago
